Company profile
IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DAROVASERTIB | phase2_3 | — | 3 | active |
| Tuvutromstat | phase1 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05907954 | phase2 | active_not_recruiting | 2023-07-03 | 2027-04-30 | IDEAYA Biosciences | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma |
| NCT07503808 | phase1 | recruiting | 2026-02-24 | 2027-07-30 | IDEAYA Biosciences | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types |
| NCT07174583 | phase1_2 | recruiting | 2025-10-14 | 2029-07-01 | IDEAYA Biosciences | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer |
| NCT07277413 | phase1 | recruiting | 2026-03-04 | 2028-04-30 | IDEAYA Biosciences | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors |
| NCT05787587 | phase1 | active_not_recruiting | 2023-04-18 | 2026-10-01 | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.